Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 18;12(2):466. doi: 10.3390/cancers12020466

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of venetoclax on MDR in drug-selected ABCG2-overexpressing cells. (A) IC₅₀ of mitoxantrone in NCI-H460 and NCI-H460/MX20 with/without venetoclax and KO143. (B) IC₅₀ of topotecan in NCI-H460 and NCI-H460/MX20 with/without venetoclax and KO143. (C) IC₅₀ of SN-38 in NCI-H460 and NCI-H460/MX20 with/without venetoclax and KO143. (D) IC₅₀ of cisplatin in NCI-H460 and NCI-H460/MX20 with/without venetoclax and KO143. (E) IC₅₀ of mitoxantrone in S1 and S1-M1-80 with/without venetoclax and KO143. (F) IC₅₀ of topotecan in S1 and S1-M1-80 with/without venetoclax and KO143. (G) IC₅₀ of SN-38 in S1 and S1-M1-80 with/without venetoclax and KO143. (H) IC₅₀ of cisplatin in S1 and S1-M1-80 with/without venetoclax and KO143. Columns with error bars represent mean ± SD from 3 independent triplicate experiments. Asterisks (*) indicate p < 0.05 versus parental group (H460 or S1).